menu search

UBX / Unity (UNX) Down on Disappointing Results From Wet AMD Study

Unity (UNX) Down on Disappointing Results From Wet AMD Study
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study. Read More
Posted: Mar 28 2023, 16:45
Author Name: Zacks Investment Research
Views: 102438

UBX News  

Unity (UNX) Down on Disappointing Results From Wet AMD Study

By Zacks Investment Research
March 28, 2023

Unity (UNX) Down on Disappointing Results From Wet AMD Study

Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD s more_horizontal

Why Is Unity Biotechnology (UBX) Stock Down 52% Today?

By InvestorPlace
March 27, 2023

Why Is Unity Biotechnology (UBX) Stock Down 52% Today?

Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is more_horizontal

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

By Benzinga
October 5, 2021

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

By Benzinga
October 5, 2021

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

By Benzinga
October 5, 2021

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

By Benzinga
October 5, 2021

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

By Benzinga
October 5, 2021

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal


Search within

Pages Search Results: